T-1095

T-1095
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

T-1095 is an investigational drug that was developed as a potential treatment for type 2 diabetes mellitus. It belongs to a class of drugs known as sodium-glucose transport protein inhibitors, specifically targeting the sodium-glucose transport protein 2 (SGLT2) in the kidneys.

Mechanism of Action

T-1095 functions by inhibiting the SGLT2 protein, which is responsible for the reabsorption of glucose in the proximal tubules of the kidneys. By blocking this protein, T-1095 reduces the reabsorption of glucose back into the bloodstream, leading to increased excretion of glucose in the urine. This process, known as glucosuria, helps to lower blood glucose levels in patients with type 2 diabetes.

Development and Research

T-1095 was developed by Tanabe Seiyaku Co., Ltd., a pharmaceutical company based in Japan. The drug was part of a broader effort to develop novel treatments for diabetes that do not rely on insulin or insulin sensitizers. Preclinical studies demonstrated that T-1095 effectively reduced blood glucose levels in animal models of diabetes.

Clinical trials were conducted to evaluate the safety and efficacy of T-1095 in humans. Early-phase trials showed promise, with patients experiencing significant reductions in blood glucose levels and HbA1c, a marker of long-term glucose control. However, further development was halted due to concerns about side effects and the emergence of more effective SGLT2 inhibitors.

Side Effects

The most common side effects associated with T-1095 were related to its mechanism of action, including increased urination and potential dehydration. Other side effects included urinary tract infections and genital infections, which are common with SGLT2 inhibitors due to the increased glucose concentration in the urine.

Comparison with Other SGLT2 Inhibitors

T-1095 was one of the first SGLT2 inhibitors to be developed, paving the way for other drugs in this class, such as canagliflozin, dapagliflozin, and empagliflozin. These newer drugs have been shown to have a more favorable safety profile and greater efficacy, leading to their approval and widespread use in the treatment of type 2 diabetes.

Also see

• Type 2 diabetes mellitus
• Sodium-glucose transport protein 2
• SGLT2 inhibitors
• Canagliflozin
• Dapagliflozin
• Empagliflozin

Template:SGLT2 inhibitors